What are the symptoms and treatment of Legionnaires' disease?

Legionnaires' Disease: Symptoms and Treatment

Clinical Presentation

Legionnaires' disease presents as severe pneumonia with high fever, cough, and dyspnea, but cannot be reliably distinguished from other pneumonias by clinical features alone, requiring a high index of suspicion based on epidemiologic risk factors and suggestive laboratory abnormalities. 1

Cardinal Respiratory Symptoms

• Cough is a hallmark feature, typically dry initially, though sputum production may develop 1, 2
• Dyspnea (shortness of breath) accompanies the pneumonia 1
• Pleuritic chest pain may occur 2
• Rales and altered breath sounds on physical examination are common but neither sensitive nor specific 1

Systemic Features

• High-grade fever (typically >39°C) is persistent and characteristic 1, 3
• Chills and flu-like symptoms are common 2
• Relative bradycardia (pulse-temperature dissociation) may be present 2

Neurological Manifestations

• Confusion, altered mental status, or encephalopathy can occur and suggest the diagnosis 1, 3
• CNS manifestations are part of the characteristic constellation of findings 4

Gastrointestinal Symptoms

• Diarrhea is a distinguishing feature that helps differentiate Legionnaires' disease from other pneumonias 2

Suggestive Laboratory Abnormalities

• Hyponatremia (low sodium) is a highly suggestive finding 1, 5, 3
• Elevated lactate dehydrogenase (LDH >700 U/mL) supports the diagnosis 4, 1
• Increased liver enzymes (particularly a 2:1 AST:ALT ratio) may be present 3, 6
• Non-purulent sputum despite severe pneumonia 3

Key Epidemiologic Risk Factors

• Recent travel with overnight stay outside the home 1
• Exposure to spas, hot tubs, or cooling towers 1
• Recent changes in domestic plumbing 1
• Advanced age, smoking, chronic lung disease, or diabetes 1
• Immunosuppression (transplant recipients, malignancy, end-stage renal disease) 1

Severity and Mortality

• Mortality ranges from 5-25% in immunocompetent hosts and up to 40% in ICU patients or immunocompromised individuals 1
• Legionella is one of the two major pathogens in severe CAP requiring ICU admission 4

---

Treatment Approach

For hospitalized patients with Legionnaires' disease, initiate either levofloxacin 750 mg IV/PO daily or azithromycin 1000 mg IV on day 1 then 500 mg IV/PO daily, with fluoroquinolones preferred for severe disease due to more rapid clinical response. 7

First-Line Antibiotic Therapy

For Hospitalized Patients (Preferred Regimens):

• Levofloxacin 750 mg IV/PO once daily 7
• Moxifloxacin 400 mg IV/PO once daily 7
• Azithromycin 1000 mg IV on day 1, then 500 mg IV/PO daily 7

For Non-Hospitalized Patients:

• Levofloxacin 750 mg PO daily 7
• Azithromycin 500 mg PO on day 1, then 250 mg PO daily 7
• Clarithromycin 500 mg PO twice daily 7
• Erythromycin 500 mg PO four times daily 7
• Doxycycline 100 mg PO twice daily 7

Duration of Treatment

• Standard duration: 7-10 days for immunocompetent patients 7
• Extended duration: 14-21 days for immunocompromised patients 7

Severity-Based Algorithm

For Severe/ICU Cases:

• Use IV fluoroquinolone as first choice (levofloxacin or moxifloxacin preferred) 7
• Consider adding rifampin to the primary regimen for severely ill or immunocompromised patients 7
• Fluoroquinolones show more rapid defervescence, fewer complications, and shorter hospital stays compared to macrolides 7

For Hospitalized Non-ICU Cases:

• Either IV/PO fluoroquinolone or macrolide is appropriate 7
• Transition from IV to oral therapy once clinically stable 7

For Mild-Moderate Outpatient Cases:

• Oral fluoroquinolone or macrolide therapy 7

Critical Treatment Principles

• Initiate treatment as rapidly as possible upon suspicion—delay is associated with increased mortality 7, 8
• Beta-lactam antibiotics are completely ineffective against Legionella and should never be used as monotherapy 7
• Failure to respond to beta-lactam therapy should prompt testing for Legionella 4
• Treatment should begin on clinical suspicion even before diagnostic confirmation 4, 7

Diagnostic Testing (To Guide Treatment)

• Urinary antigen assay detects 80-95% of L. pneumophila serogroup 1 cases and is the most practical test 7
• Culture of respiratory secretions on selective media is the gold standard but takes longer 4, 7
• Testing is recommended for all patients with severe CAP requiring ICU admission, enigmatic pneumonia, or failure to respond to beta-lactam therapy 4

Common Pitfalls to Avoid

• Do not delay treatment waiting for diagnostic confirmation—empiric therapy based on clinical suspicion is critical 7, 8
• Do not use beta-lactam monotherapy even if other pathogens are suspected—Legionella requires macrolide or fluoroquinolone coverage 7
• Do not routinely use rifampin combination therapy—reserve it for severe cases or immunocompromised hosts 7
• Do not undertreated immunocompromised patients—they require longer duration (14-21 days) 7
• Be aware that macrolide resistance is increasing in some regions, which may affect treatment efficacy 7